At peak demand in 2024, compounded GLP-1s represented roughly 30% of total US GLP-1 supply
The possible mechanisms by which SGLT2 inhibitors reduce cardiovascular risk are unknown, but are likely to include reductions in hyperglycemia and body weight, osmotic diuresis, and reduced blood pressure [52,53,54]
Ehrenkranz, R
Semaglutide (Wegovy) has demonstrated cardiovascular risk reduction in clinical trials, reducing the risk of major cardiovascular events by 20%
Domperidone has MHRA restrictions due to cardiac risks (QT prolongation) and should only be used at the lowest effective dose for the shortest duration
During pregnancy, ensuring that the mother and unborn baby both get enough vitamin B12, which is important for brain development and other functions